{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:00:27Z","timestamp":1787497227432,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>This review provides a comprehensive overview of cardiac electrophysiology principles as they apply to oncology care, with a focus on QT interval assessment and monitoring. Accurate measurement of the QT interval and appropriate heart rate correction\u2014particularly using the tangent method and Fridericia formula\u2014are essential for evaluating arrhythmic risk in cancer patients, who are especially vulnerable due to the cardiotoxic potential of many chemotherapeutic agents. We highlight key risk factors for QT prolongation, including electrolyte imbalances, underlying cardiac conditions, and concurrent use of QT-prolonging medications. Current cardiac monitoring protocols during chemotherapy are examined, with specific reference to clinical practices at The University of Texas MD Anderson Cancer Center. These practices underscore the importance of structured surveillance and timely intervention. Effective management requires a multi-pronged approach involving standardized measurement techniques, proactive risk stratification, and patient education. Counseling patients on symptoms such as palpitations, dizziness, or syncope facilitates early detection and evaluation. Given the expanding list of QT-prolonging agents, clinicians are encouraged to use resources like Torsades.org for up-to-date drug information. In the absence of formal guidelines for certain agents, institution-specific protocols defining thresholds for treatment initiation, dose adjustment, and monitoring frequency are critical for ensuring consistency, safety, and evidence-based decision-making in cardio-oncology.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1748382","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:43:03Z","timestamp":1779169383000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["QT monitoring in chemotherapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Peter Y.","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keila Carolina","family":"Ostos Mendoza","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Fernanda","family":"L\u00f3pez Moreno","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Casso-Chapa","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah I.","family":"Beinart","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Paniagua-Bojorges","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Mariana","family":"Ruesta Carrion","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Assunto","family":"Lenz","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Wamique","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Koutroumpakis","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Abe","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ewer","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.12669\/pjms.315.8998","article-title":"Antipsychotic medication and QT prolongation","volume":"31","author":"Chohan","year":"2015","journal-title":"Pak J Med Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40360-016-0053-1","article-title":"Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect\u2014comprehensive overview of clinical trials","volume":"17","author":"Wisniowska","year":"2016","journal-title":"BMC Pharmacol Toxicol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/bjc.2015.82","article-title":"Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors","volume":"112","author":"Kloth","year":"2015","journal-title":"Br J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","article-title":"Effect of arsenic trioxide on QT interval in patients with advanced malignancies","volume":"21","author":"Barbey","year":"2003","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/15360288.2021.1900491","article-title":"The risk of QTc prolongation with antiemetics in the palliative care setting: a narrative review","volume":"35","author":"Gavioli","year":"2021","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1161\/CIRCULATIONAHA.111.080887","article-title":"Clinical and genetic determinants of torsade de pointes risk","volume":"125","author":"Sauer","year":"2012","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology foundation","volume":"55","author":"Drew","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","article-title":"Managing drug-induced QT prolongation in clinical practice","volume":"97","author":"Khatib","year":"2021","journal-title":"Postgrad Med J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bcp.12726","article-title":"Pharmacological treatment of acquired QT prolongation and torsades de pointes","volume":"81","author":"Thomas","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B10","volume-title":"Physiology, Cardiac Repolarization Dispersion and Reserve","author":"Wei","year":"2025"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s42826-021-00102-3","article-title":"A comparative review on heart ion channels, action potentials and electrocardiogram in rodents and human: extrapolation of experimental insights to clinic","volume":"37","author":"Joukar","year":"2021","journal-title":"Lab Anim Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart"},{"key":"B13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jelectrocard.2004.08.030","article-title":"A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs","volume":"37","author":"Luo","year":"2004","journal-title":"J Electrocardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.amjcard.2003.12.055","article-title":"Assessment of prolonged QT and JT intervals in ventricular conduction defects","volume":"93","author":"Rautaharju","year":"2004","journal-title":"Am J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jacc.2008.12.014","article-title":"AHA\/ACCF\/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association electrocardiography and arrhythmias committee, council on clinical cardiology; the American College of Cardiology foundation; and the heart rhythm society. Endorsed by the international society for computerized electrocardiology","volume":"53","author":"Rautaharju","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaccao.2021.01.002","article-title":"How to diagnose and manage QT prolongation in cancer patients","volume":"3","author":"Kim","year":"","journal-title":"JACC CardioOncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"613625","DOI":"10.3389\/fcvm.2021.613625","article-title":"QT Prolongation in cancer patients","volume":"8","author":"Kim","year":"","journal-title":"Front Cardiovasc Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.2146\/ajhp120253","article-title":"Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer","volume":"70","author":"Ton","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/bjd.17465","article-title":"A prospective observational safety study of patients with BRAF(V) (600) -mutated unresectable or metastatic melanoma treated with vemurafenib (zelboraf safety study)","volume":"180","author":"Corrie","year":"2019","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1126\/science.1183424","article-title":"Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML","volume":"328","author":"Zhang","year":"2010","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12272-023-01481-y","article-title":"Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date","volume":"47","author":"Yan","year":"2024","journal-title":"Arch Pharm Res"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1748382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:43:08Z","timestamp":1779169388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1748382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":21,"alternative-id":["10.3389\/fcvm.2026.1748382"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1748382","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"1748382"}}